摘要
目的:探讨肾移植术后应用环孢素A(CsA)、强的松(Pred)和吗替麦考酚酯(MMF)后是否允许CsA减量而不增加排斥反应发生率,是否可以减少CsA相关副作用以提高疗效。方法:将使用常规剂量CsA的肾移植患者(213例)与使用低剂量CsA患者(176例)进行对照研究。结果:2组肾功能水平、排斥反应发生率及人/肾存活率均无显著性差异,但低剂量CsA组总体疗效稍好,而且不良反应发生率明显减少。结论:肾移植术后患者CsA+MMF+Pred三联用药,在使用足够剂量MMF的情况下,可以允许CsA减量而不增加急性排斥反应的风险。
OBJECTIVE： To discuss whether a reduced dose of CsA was allowed yet without increase risk of rejection, and whether the incidence of CsA- related side effects be reduced while the curative effects be enhanced by combined use of Cyclosporine （CsA）, prednisone and Mycophenolate Mofetil （MMF） in patients after renal transplantation. METHODS： In this comparative study, 213 renal allograft recipients receiving routine dose of CsA were compared with 176 cases receiving low dose CsA. RESULTS： The two groups showed no significant differences in renal function, incidence of rejection and human/kidney survival rate. However, the low dose CsA group showed a better total curative efficacy and significantly fewer incidences of ADRs. CONCLUSION： CsA, MMF and Pred used concomitantly in patients after renal transplantation allows for a reduced dose of CsA yet without increase the risk of acute rejection if with enough dose of MMF.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第11期844-845,共2页
China Pharmacy
关键词
肾移植
环孢素A
吗替麦考酚酯
Renal transplantation
Cyclosporine A
Mycophenolate Mofetil
